Hank BondWalther

Partner

Washington + 1.202.879.3432

Connect:

Share

Hank Walther defends companies and individuals in complex criminal cases and conducts high-stakes internal investigations for leading companies around the globe. Hank defends companies and individuals that are facing criminal prosecution and civil liability from numerous government agencies and civil litigants, often in multiple countries. During his more than 20 years of practice, as both a defense attorney and federal prosecutor, Hank has led fraud and corruption investigations in more than 35 countries around the world.

Since joining Jones Day, Hank has conducted investigations for and defended industry-leading companies in the health care, technology, retail, extraction, engineering, and automotive industries. He has also successfully defended numerous senior corporate executives and government officials, recently obtaining a post-indictment dismissal of all charges against a corporate executive in an alleged $8 billion fraud scheme. Prior to joining Jones Day, Hank was a federal prosecutor in the Department of Justice's (DOJ) Criminal Division, Fraud Section, where he served as a line prosecutor, a supervisor in the Foreign Corrupt Practices Unit, and Chief of the Health Care Fraud Unit.

Hank has been recognized as a leading white collar lawyer by Chambers USA, Washingtonian magazine, The Legal 500, and Super Lawyers. Chambers has described Hank as "a go-to for complicated government matters," "a tremendous advocate," and "a trial animal" who has "instant credibility with DOJ."

Experience

  • CEO of international logistics company obtains post-indictment dismissal of all chargesJones Day obtained a post-indictment Non-Prosecution Agreement and dismissal of all charges against the former CEO of an international logistics company charged with engaging in an alleged multi-billion dollar fraud scheme and violating OFAC laws.
  • Global healthcare company obtains declinations from DOJ and SEC after multi-year investigation into corruption in Asia and EuropeJones Day obtained declinations from DOJ and the SEC on behalf of a global healthcare company that was under investigation for allegations of making improper payments in Asia and Europe.
  • Global financial institution obtains declination from DOJ after investigation into alleged foreign currency exchange rate manipulation in multiple countriesJones Day obtained a declination from DOJ on behalf of a global financial institution that was investigated for alleged foreign currency exchange rate manipulation in multiple countries.
  • Professional sports team defends DOJ investigation into corruption and OFAC issuesJones Day is defending a professional sports team in a DOJ investigation into allegations of corruption and OFAC violations in Latin America.
  • National retailer defends allegations of corruption in Latin America and AsiaJones Day is representing a national retailer in an internal investigation into allegations of corruption in multiple countries in Latin America and Asia and related DOJ and SEC investigations.
  • President of health care company defends allegations of improper billingJones Day represents the former President of a health care company in a DOJ investigation into allegations of improper billing and upcoding.
  • Energy company defends investigation into foreign advanced nuclear technology and reactor-project developmentJones Day successfully represented an energy company under investigation by the Nuclear National Security Administration for transferring nuclear technology to China.
  • Jones Day advises on UK's first Deferred Prosecution Agreement and closure of U.S. DOJ investigationOn Monday, November 30, 2015, the Right Honourable Sir Brian Leveson (the President of the Queen's Bench Division) approved the resolution of the first UK Bribery Act section 7 proceedings by way of a Deferred Prosecution Agreement, a procedure never before used in the UK.
  • Oil and gas company conducts internal investigation into allegations of corruption in AsiaJones Day represented a publicly-traded oil and gas company in an internal investigation into allegations of corruption in Asia.
  • Medical device company conducts internal investigation into allegations of off-label marketingJones Day represented a publicly-traded medical device company in an internal investigation into allegations of off-label marketing.
  • Executive of manufacturing company defends allegations of corruption in AsiaJones Day represented an executive from a global manufacturing company in a DOJ investigation into allegations of corruption in Asia.
  • Owner of medical supply company defends allegations of health care kickbacksJones Day represented an owner of a medical supply company in a Health and Human Services investigation into allegations of health care kickbacks.
  • National law firm defends allegations of money launderingJones Day represented a national law firm in an investigation into allegations of money laundering.
  • Technology company conducts internal investigation into allegations of corruption in Eastern EuropeJones Day represented a publicly-traded technology company in an internal investigation into allegations of corruption in Eastern Europe.
  • Executive of medical device company defends allegations of corruption in Latin AmericaJones Day represented an executive from a publicly-traded medical device company in a DOJ and SEC investigation into allegations of corruption in Latin America.
  • Hospital system successfully resolves false claims for transport servicesJones Day represented a hospital system in a False Claims Act investigation into false claims for transport services.
    • View All

    March 2024 Commentary

    DOJ Announces New Whistleblower Program and Enforcement Initiatives

    February 2024 Alert

    DOJ's Antitrust Division and the FTC Announce New Guidance on Preservation for Collaboration Tools and Ephemeral Messaging

    January 2024 White Paper

    FCPA 2023 Year In Review

    October 2023 White Paper

    Considerations for Addressing DOJ's Corporate Compliance Guidance on Mobile Devices and Messaging Platforms

    October 2023 Alert

    DOJ Announces Safe Harbor Policy for Voluntary Self-Disclosures in Mergers and Acquisitions

    July 2023 Commentary

    Australia: National Anti-Corruption Commission Commences Operations

    May 2023 White Paper

    Jones Day Cross-Border Investigations Series 2023: Whistleblowing

    April 2023 White Paper

    Insider Trading Enforcement in 2022

    April 2023 Alert

    U.S. Supreme Court Rules That the FSIA Does Not Grant Foreign State-Owned Entities Immunity From Prosecution

    March 2023 Commentary

    DOJ Updates Corporate Compliance Program Guidance and Announces New Policy Initiatives and Enforcement Resources
    View All

    Additional Publications

    • March 2019
      FCPA Self-Disclosure Marches on in Year II of Trump Administration, Corporate Counsel Business Journal

    Speaking Engagements

    • September 27, 2017
      PLI's Storming the Gatekeepers: When Compliance Officers and In-House Lawyers Are at Risk 2017
    • April 20, 2017
      The State of the Union: FCPA Enforcement in a Trump Administration, 19th Annual New York Conference on the Foreign Corrupt Practices Act, American Conference Institute
    • January 12, 2017
      The FCPA’s Jurisdictional Hooks – How Far Do They Reach, Who Can They Ensnare?, Eleventh Annual National Institute on Securities Fraud, American Bar Association
    • September 21, 2016
      The French Anti-corruption Bill / Loi Sapin II – Crossed Views: France – United States
    • September 21, 2016
      Sapin ll and International Anti-Corruption Developments
    • 21 septembre 2016
      Loi Sapin II : Anti-corruption - Regards croisés France - Etats-Unis
    • February 9, 2016
      First Deferred Prosecution in the UK, US Department of Justice agrees to close investigation
    • December 1, 2015
      Anti-Corruption Congress
    • May 14-15, 2015
      2015 Health Care Labor & Employment Symposium
    • September 26, 2013
      Executive Roundtable Series - Responding to a Government Investigation: Defending the Company and Its People and Protecting Its Reputation
    • April 9-10, 2013
      Jones Day 2013 Chicago Health Care Conference
    • May 8-9, 2012
      FCPA and Anti-Corruption for the Life Sciences Industry 6th National Conference
    • April 19, 2012
      Qui Tam Litigation: When Private Parties Pursue Claims for the Government
    • March 28, 2012
      Health Care 2012: Issues and Answers for a Complex Industry
    • March 28, 2012
      Healthcare 2012: Issues & Answers For A Complex Industry
    • March 15-16, 2012
      Global Ethics Summit 2012, Thomson Reuters and the Ethisphere Institute
    • November 16, 2011
      Medicare Fraud Strike Force: 2011 and Beyond, National Health Care Anti-Fraud Association, Annual Training Conference
    • November 15, 2011
      Law Enforcement Strategies, Global Health Care Anti-Fraud Network, Global Health Care Fraud Prevention Summit
    • May 12, 2011
      Government Enforcement Panel, American Bar Association, 21st National Institute on Health Care Fraud
    • January 25, 2011
      Understanding the Department of Justice’s Enforcement Priorities: Steering Clear of Criminal and Civil Liability When Conducting Clinical Trials, American Conference Institute, Advanced Forum on Clinical Trials
    • January 24, 2011
      Trends in Enforcement: Areas of Focus for State and Federal Prosecutors, Center for Business Intelligence, Pharmaceutical Compliance Conference
    • December 7, 2010
      Enforcement and Compliance Roundtable, American Bar Association, Washington Healthcare Summit
    • November 17, 2010
      Medicare Fraud Strike Force: 2010 and Beyond, National Health Care Anti-Fraud Association, Annual Training Conference
    • August 5, 2010
      The Shift in Focus to Individuals in FCPA Prosecutions, American Bar Association, 2010 Annual Meeting
    • June 28, 2010
      HEAT Anti-Fraud Initiative – Florida: Come for the Fraud and Stay for the HEAT, American Health Lawyer’s Association, 2010 Annual Meeting
    • June 23, 2010
      Personal Liability: How the Shift Towards Individual Prosecution Will Affect You and Minimize FCPA Risks Before, During, and After M&A, Ethical Corporation 3rd Annual Global Anti-Corruption Summit USA
    • May 18, 2010
      U.S. and International FCPA and Anti-Corruption Enforcement Priorities, American Conference Institute, FCPA and Anti-Corruption for Life Science Companies Conference
    • May 14, 2010
      Trial Practice Demonstration: United States v. Valladares, American Bar Association, 20th National Institute on Health Care Fraud
    • March 23, 2010
      Structuring Cost-Efficient Internal Investigations of Improper Payments, American Conference Institute, National Conference on the Foreign Corrupt Practices Act
    • February 23, 2010
      When the Government Comes Knocking, Ethisphere Global Ethics Summit

    Before sending, please note:

    Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.